Redoxis and Image Analysis have been awarded more than 1.2 million euros from a Eurostars research fund to develop an advanced in vivo imaging service for preclinical models to improve therapies in autoimmune diseases.
Redoxis and Image Analysis received the E - IMAID Eurostars grant funding to help address unmet medical needs in the field of inflammatory autoimmune diseases and conditions. The advanced in vivo imaging approach is expected to provide a cost-effective service in the evaluation of preclinical models of drugs for autoimmune conditions and orphan diseases for the pharmaceutical and biotech industry, the firms said.
Redoxis specializes in immunology, animal models, and target validation with in vivo and in vitro models of autoimmune inflammation, while Image Analysis has medical experts in imaging technology who will provide new systems based on analytics from MRI such as DEMRIQ, a proprietary semiautomatic quantification method of inflammatory processes that explores imaging biomarkers for orphan diseases. The main objectives of the project are implementation of current animal models of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
